Savara Inc.
SVRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Savara Inc. (SVRA) is listed under Biotechnology. With a market capitalization of $864.8M, it sits in small-cap territory. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Market Cap
$864.8M
Beta
0.20
P/E (TTM)
—
P/E (Fwd)
-11.50
EPS (TTM)
$-0.56
EPS (Fwd)
$-0.37
ROE
-105.5%
ROA
-50.1%
Cash
$174.8M
Total Debt
$30.4M
Free CF
-$57.2M
52W Change
-3.6%
Annual Financials
Cash vs Debt
Where SVRA stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, SVRA finished 17.13% below its 150-day moving average ($5.37) and 18.35% below its 200-day moving average ($5.45). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SVRA overbought or oversold?
At the October 19, 2026 close, SVRA's RSI(14) was 28.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $174.8M in cash and $30.4M in debt, SVRA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$57.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -105.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta below 0.7, Savara Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, SVRA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Savara Inc. and its sector.